Development of Eye-tracking Based Markers for Autism in Young Children

October 26, 2018 updated by: Keith Kendrick, University of Electronic Science and Technology of China

Evaluation of Five Different Eye-tracking Paradigms to Determine Autism in Young Children

The main aim of the present study is to examine eye-tracking based markers for social processing deficits in children with autism spectrum disorder (ASD). To this end a battery of five eye-tracking paradigms will be administered to young children with ASD and typically developing children. To additionally evaluate the specificity of the eye-tracking markers a group of children with disorders of delayed development other than ASD will be included.

Study Overview

Status

Completed

Detailed Description

During an initial screening session all participants will undergo the Autism Diagnostic Observation Schedule (ADOS). ASD-related symptomatology and levels of impairments will be further characterized using the Social Responsibilities Scale 2 (SRS 2), Caregiver Strain Questionnaire (CSQ), Aberrant Behavior Checklist (ABC), Social Communication Questionnaire (SCQ), and Repetitive Behaviour Scale Revised (RBS-R).

Subsequently all participants will be administered the following eye-tracking paradigms: (1) dynamic social and non-social visual preference paradigm during which dynamic geometric images (DGI) and dynamic social images (DSI) will be presented, (2) non-biological versus biological motion paradigm, (3) social attention and sharing of enjoyment paradigm, (4) preference for real versus schematic emotional face stimuli paradigm during which photographs of human faces and emoticons will be presented, (5) shared social attention and gaze direction paradigm.

Study Type

Observational

Enrollment (Actual)

70

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sichuan
      • Chengdu, Sichuan, China, 610054
        • School of Life Science and Technology, University of Electronic Science and Technology of China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

1 year to 10 years (Child)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Children with ASD according to DSM-5 criteria will be compared with typically developing children and a group of children with unspecific delayed development disorders.

Description

Exclusion criteria for all participants:

  • visual, auditory or motor impairments
  • use of medication

Inclusion criteria for all participants:

  • written informed consent from parents / caregiver
  • age: 1-10 years

Additional inclusion criterion for the ASD group:

- diagnosis of Autism Spectrum Disorder according to DSM-5

Additional inclusion criteria for typically developing children in the control group:

  • no symptoms of developmental disorders
  • no current or history of psychological disorder

Additional inclusion criterion for the unspecific disorder of delayed development children in the additional control group:

- disorder of delayed development other than ASD

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Control
  • Time Perspectives: Cross-Sectional

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Children with Autism Spectrum Disorder
Children with an Autism Spectrum Disorder according to DSM-5 criteria
All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
Typically Developing Children
Typically developing children
All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
Children with Delayed Development Disorders
Children with Delayed Developmental Disorders other than ASD
All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global eye-gaze characteristics
Time Frame: Single assessment, total duration 20 minutes
Global eye-gaze patterns between the three groups will be compared to determine ASD specific alterations
Single assessment, total duration 20 minutes
Feature-specific eye-gaze characteristics
Time Frame: Single assessment, total duration 20 minutes
Localized feature-specific eye-gaze patterns will be compared between the three groups to determine ASD specific alterations
Single assessment, total duration 20 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Global eye-gaze characteristics and associations with symptom severity
Time Frame: Single assessment, total duration 20 minutes
Associations between global eye-gaze characteristics and severity of ASD symptoms
Single assessment, total duration 20 minutes
Feature-specific eye-gaze characteristics and associations with symptom severity
Time Frame: Single assessment, total duration 20 minutes
Associations between localized feature-specific eye-gaze patterns and severity of ASD symptoms
Single assessment, total duration 20 minutes

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Juan Kou, MSc, University of Electronic Science and Technology of China

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 9, 2017

Primary Completion (Actual)

February 28, 2018

Study Completion (Actual)

February 28, 2018

Study Registration Dates

First Submitted

September 14, 2017

First Submitted That Met QC Criteria

September 15, 2017

First Posted (Actual)

September 18, 2017

Study Record Updates

Last Update Posted (Actual)

October 29, 2018

Last Update Submitted That Met QC Criteria

October 26, 2018

Last Verified

October 1, 2018

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Autism Spectrum Disorder

Clinical Trials on Administration of five eye-tracking paradigms

3
Subscribe